PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Blood Cancer Discovery0 citations

Models, Models, Everywhere: But Which One Should Guide Care?

View Full Paper
CLCurtis A. LachowiezOregon Health & Science UniversitySLSanam LoghaviThe University of Texas MD Anderson Cancer Center

Key Points

  • To develop a therapy-specific prognostic model that integrates mutational and cytogenetic features for acute myeloid leukemia.
  • Developed a prognostic model using mutational and cytogenetic data
  • Evaluated survival outcomes in patients treated with venetoclax-based regimens
  • Compared findings with existing prognostic models
  • The model effectively stratified patients based on risk of survival
  • Integration of mutational and cytogenetic features improved risk assessment
  • Findings provide a framework for clinical decision-making

Abstract

Summary: Drekolias and colleagues report a therapy-specific prognostic model integrating mutational and cytogenetic features to risk-stratify survival in patients with acute myeloid leukemia treated with venetoclax-based regimens, providing a clinically relevant framework amid a rapidly expanding landscape of competing models. See related article by Drekolias et al., p. XX .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lachowiez et al. (2026) studied this question.

synapsesocial.com/papers/69cd7b695652765b073a9656https://doi.org/10.1158/2643-3230.bcd-26-0055
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine2024 · 148 citations
  2. 2Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia2024 · 219 citations
  3. 3Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML2025 · 3 citations
  4. 4Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study2025 · 7 citations
  5. 5Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia2020 · 2,891 citations